Immunohistochemistry is currently assessed and approved as the reference method to evaluate PD-L1 expression in tissue as a predictive factor for the activity and efficacy of immune checkpoint inhibitors in a number of solid tumors, including NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.